By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is bearish on CRISPR Therapeutics, with key concerns being the company's reliance on multiple binary bets for upside, reimbursement friction, and manufacturing challenges. The potential of CRISPR's gene-editing platform and in-vivo editing are seen as speculative opportunities.
Risk: Reimbursement friction and manufacturing challenges
Opportunity: Successful transition to in-vivo editing
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
CRISPR's Casgevy cements the company as a leader in gene-editing therapies.
The company's commercial momentum should build as Casgevy reaches more patients.
A healthy pipeline and modest market cap make CRISPR a no-brainer to hold for the next decade.
For years, CRISPR Therapeutics (NASDAQ: CRSP) has been the type of stock investors might call a home run swing. The company develops medicines using gene-editing technologies to treat or cure serious conditions and diseases that traditional pharmaceutical drugs cannot.
The stock has generated good returns over time, but it's been a very bumpy ride at times. Today, CRISPR Therapeutics' stock trades at a fraction of its former price. However, Wall Street analysts see opportunity. On CNN Business, 58% of Wall Street analysts have rated CRISPR Therapeutics as a buy, with price targets signaling as much as 437% upside.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Here's a look at why analysts might be bullish.
CRISPR Therapeutics has been around for years, but it only recently commercialized its first product. Casgevy is a gene editing treatment co-developed with Vertex Pharmaceuticals to treat sickle cell disease and transfusion-dependent beta thalassemia. It's a one-time treatment tailored to each patient's edited DNA that functionally mutes the disease, coming as close to a functional cure as you can get.
It takes time to treat patients with Casgevy; patients submit a sample of their DNA, which is edited and then reintroduced into the patient. CRISPR and Vertex received FDA approval in late 2023. Yet only 64 patients received Casgevy infusions in 2025.
The company generated $4.1 million in sales last year. Analysts see revenue growing to $43.9 million this fiscal year and to $151.6 million next fiscal year.
One-time treatments don't generate recurring revenue, but there's a vast patient pool. CRISPR estimates 60,000 eligible patients are in the United States and other countries where the therapy is approved.
The stock doesn't look cheap at first glance. At its current market cap of $5.4 billion, CRISPR still trades at roughly 35 times next year's revenue estimates. But things change as you zoom out.
CRISPR has a strong pipeline, with five other therapies at various stages of clinical trials. If even one or two of those hit, it's a potential game changer. CRISPR wholly owns four of those five therapies, meaning significantly more financial upside if they make it through trials and to the market. In the meantime, Casgevy will continue to grow and create a financial floor for the company.
Some of the world's largest pharmaceutical companies are worth hundreds of billions of dollars. CRISPR Therapeutics has a long way to go, but the ceiling is quite high. Gene editing produced a revolutionary treatment in Casgevy, and it can duplicate that success in some of the harshest known diseases, where traditional pharmaceuticals have failed.
This is all still highly speculative, so investors should tread carefully. That said, CRISPR's relatively modest market cap and its first big win with Casgevy make the stock a potential home run over the next decade, worth buying and holding to take that swing. If things go well, that 437% upside from analysts doesn't look so outlandish at all.
Before you buy stock in CRISPR Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CRISPR Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $449,393! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,366,006!
Now, it’s worth noting Stock Advisor’s total average return is 983% — a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of June 3, 2026. *
Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"The bullish case rests on multiple pipeline successes and Casgevy adoption, but execution, pricing, and regulatory risks could prevent that upside from materializing."
CRISPR Therapeutics is riding a positive Casgevy narrative, but the implied upside hinges on a rapid, multi-year ramp in a very small revenue base. 2025 saw only 64 infusions; 2026 consensus calls for $151.6m, implying a steep growth trajectory and a potential floor from one-time edits. The pipeline adds optionality but also dilution and timing risk: five other therapies with uncertain probabilities of success. Manufacturing complexity, payer coverage, and potential regulatory setbacks could cap adoption long before the leverage from a high multiple is realized. In short, upside looks conditional on multiple binary bets, not a guaranteed outcome.
Even if Casgevy scales, a few failed trials or slower adoption could wipe out upside; the market pricing already accounts for substantial optionality, and a major setback could erase most gains.
"The market is overestimating the speed of commercial adoption for Casgevy while underestimating the execution risk and capital intensity required to bring the rest of the pipeline to market."
The article's 437% upside thesis relies on a 'venture capital' valuation model—pricing in theoretical future blockbusters while ignoring the brutal reality of commercializing cell therapies. Casgevy is a medical triumph, but its $2.2 million price tag creates massive friction in reimbursement and logistics. With only 64 patients treated in 2025, the 'commercial momentum' narrative is premature. Trading at 35x forward revenue is a massive premium for a company that must prove it can navigate the 'valley of death' in clinical trials for its remaining pipeline. Investors are essentially betting on scientific outcomes, not financial fundamentals, making this a high-beta play that is highly sensitive to interest rate volatility.
If CRISPR successfully pivots to 'off-the-shelf' allogeneic CAR-T therapies, they could disrupt the entire oncology market, making current revenue multiples look like a bargain in hindsight.
"CRSP trades at 35x forward revenue on $4.1M actual sales—a speculative biotech multiple, not a 'cheap' large-cap, and the article's framing conflates pipeline optionality with current undervaluation."
The article conflates two separate questions: whether Casgevy is a commercial success (it isn't yet—64 patients and $4.1M revenue in 2025 is validation, not traction) and whether CRSP at $5.4B market cap is cheap (it's not, relative to current cash generation). The 437% upside assumes multiple pipeline wins AND massive Casgevy adoption across 60,000 patients. That's a binary bet on execution over a decade, not a valuation arbitrage. The article also omits: manufacturing scalability risks for personalized therapies, reimbursement uncertainty (payers balk at one-time $2M+ treatments), and competition from other gene-editing platforms (BEAM, VERV). At 35x next-year revenue with single-digit actual revenue, CRSP is priced for perfection, not opportunity.
If even one pipeline candidate succeeds and Casgevy adoption accelerates to 5,000+ annual patients by 2027, the current valuation becomes genuinely cheap, and the 437% target is conservative rather than absurd.
"CRSP's $5.4B market cap already prices in substantial pipeline success that remains years away and clinically uncertain."
The article overstates CRISPR's near-term prospects by highlighting 437% analyst upside and Casgevy's potential while downplaying its $5.4B market cap against projected $152M revenue next year. Gene therapies face steep reimbursement, manufacturing, and patient-access hurdles that have slowed Casgevy to just 64 infusions so far. With four wholly owned pipeline assets still in early trials, binary clinical outcomes could erase much of the current valuation before any re-rating occurs. Revenue growth from one-time treatments also lacks the recurring base that supports premium multiples in other biotech names.
Even with adoption risks, successful Phase 3 readouts in wholly owned programs could trigger rapid M&A interest from larger pharma, justifying the current multiple on optionality alone.
"Upside hinges on dilution-free scale; unless Casgevy monetizes quickly, equity dilution will erode returns and cap the 437% upside."
Gemini's 437% upside thesis ignores the dilution and cash burn required to finance five additional pipeline assets. Even if Casgevy hits scale, CRSP may need recurrent fundraising at dilutive terms, compressing the realized return and raising the hurdle for any re-rating. This is a risk not baked into the 'venture-capital' narrative and could cap upside well before Casgevy adoption accelerates.
"The shift from ex-vivo to in-vivo editing is the only viable path to justifying current multiples, yet it remains the most significant unpriced technological risk."
Claude and Grok correctly identify the valuation disconnect, but both overlook the competitive moat. CRISPR Therapeutics isn't just selling Casgevy; they are selling a proprietary gene-editing platform. If they successfully transition to in-vivo editing—bypassing the ex-vivo manufacturing bottlenecks that plague current cell therapies—the 'commercial friction' argument becomes obsolete. The real risk isn't just reimbursement; it is the rapid obsolescence of their current platform by newer, cheaper, in-vivo delivery technologies from competitors.
"In-vivo editing doesn't solve the payer friction problem; it just shifts the manufacturing bottleneck elsewhere."
Gemini's in-vivo pivot argument is speculative—CRISPR hasn't demonstrated clinical viability in in-vivo editing yet, and competitors (Verve, Beam) are also pursuing this. More critically: even if successful, in-vivo therapies face identical reimbursement friction as ex-vivo. A $2M one-time treatment is expensive whether it's manufactured in a lab or delivered intravenously. The moat argument conflates platform optionality with commercial de-risking. They're not the same.
"In-vivo cost reductions could ease both reimbursement and dilution pressures more than Claude allows."
Claude's point on persistent reimbursement friction for in-vivo therapies understates how drastically lower manufacturing costs could expand the addressable patient pool and improve unit economics. This directly intersects with ChatGPT's dilution warning: successful in-vivo transition might reduce the need for repeated equity raises, preserving more upside than current ex-vivo constraints imply. Binary trial risk remains, but the cost structure shift is underweighted.
The panel consensus is bearish on CRISPR Therapeutics, with key concerns being the company's reliance on multiple binary bets for upside, reimbursement friction, and manufacturing challenges. The potential of CRISPR's gene-editing platform and in-vivo editing are seen as speculative opportunities.
Successful transition to in-vivo editing
Reimbursement friction and manufacturing challenges